To determine the MTD of RAD001 in combination with irinotecan and cetuximab as second line therapy in patients with metastatic colorectal cancer Phase I [clinicaltrials_resource:c1465e9c2ba67e916e91b4791c8ecb9f]
Irinotecan 125 mg/m2 IV days 1 and 8
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To determine the MTD of RAD001 in combination with irinotecan and cetuximab as second line therapy in patients with metastatic colorectal cancer Phase I [clinicaltrials_resource:c1465e9c2ba67e916e91b4791c8ecb9f]
Irinotecan 125 mg/m2 IV days 1 and 8
Bio2RDF identifier
c1465e9c2ba67e916e91b4791c8ecb9f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c1465e9c2ba67e916e91b4791c8ecb9f
measure [clinicaltrials_vocabulary:measure]
To determine the MTD of RAD001 ...... h metastatic colorectal cancer
time frame [clinicaltrials_vocabulary:time-frame]
description
Irinotecan 125 mg/m2 IV days 1 and 8
identifier
clinicaltrials_resource:c1465e9c2ba67e916e91b4791c8ecb9f
title
To determine the MTD of RAD001 ...... atic colorectal cancer Phase I
@en
type
label
To determine the MTD of RAD001 ...... 65e9c2ba67e916e91b4791c8ecb9f]
@en